GlobalData on MSN9d
FDA grants breakthrough designation for Acrivon’s endometrial cancer assayThe US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...
The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...
Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...
Role of laparoscopic & robotic surgery in oncology: Dr. Arvind Kumar Wednesday, February 5, 2025, 08:00 Hrs [IST] Advancements in surgical techniques ...
It is well recognized that, in many cases, endometrial carcinoma is a well differentiated tumor bearing ... Supported in part by a National Cancer Institute research grant (C 2421).
The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer. The OncoSignature multiplex ... which is a novel, differentiated WEE1/PKMYT1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback